24,625 results match your criteria Agranulocytosis


Non-immunological toxicological mechanisms of metamizole-associated neutropenia in HL60 cells.

Biochem Pharmacol 2019 Jan 14. Epub 2019 Jan 14.

Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland; Department of Biomedicine, University of Basel, Switzerland; Swiss Centre of Applied Human Toxicology (SCAHT), Basel, Switzerland. Electronic address:

Metamizole is an analgesic and antipyretic, but can cause neutropenia and agranulocytosis. We investigated the toxicity of the metabolites N-methyl-4-aminoantipyrine (MAA), 4-aminoantipyrine (AA), N-formyl-4-aminoantipyrine (FAA) and N-acetyl-4-aminoantipyrine (AAA) on neutrophil granulocytes and on HL60 cells (granulocyte precursor cell line). MAA, FAA, AA, and AAA (up to 100 µM) alone were not toxic for HL60 cells or granulocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2019.01.011DOI Listing
January 2019

Increased Risk of Antithyroid Drugs Agranulocytosis Associated with Amiodarone-induced Thyrotoxicosis: a Population-based Cohort Study.

Thyroid 2019 Jan 16. Epub 2019 Jan 16.

Lady Davis Carmel Medical Center, Clalit Health Services, Community Medicine and Epidemiology , 7 Michal St. , Haifa, Israel , 3436212 ;

Objective: Agranulocytosis occurs in 0.2-0.5% of patients treated with the antithyroid drugs (ATDs) methimazole and propylthiouracil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2018.0274DOI Listing
January 2019

Acute agranulocytosis when switching from risperidone to paliperidone.

Aust N Z J Psychiatry 2019 Jan 14:4867418821441. Epub 2019 Jan 14.

Department of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0004867418821441DOI Listing
January 2019

Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.

AAPS PharmSciTech 2019 Jan 2;20(1):22. Epub 2019 Jan 2.

Department of Pharmaceutics, Sinhgad Institute of Pharmacy, Sinhgad Technical Education Society, Narhe, Pune, MS, 411041, India.

Potential risk of agranulocytosis is one of the drug-induced adverse effects of the second-generation antipsychotic agents. The present investigation aimed to formulate and investigate olanzapine (OLZ)-loaded nanostructured lipid carriers (OLZ-NLCs) via intranasal (i.n. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12249-018-1213-yDOI Listing
January 2019

5-HT deletion protects against Clozapine-induced hyperglycemia.

J Pharmacol Sci 2018 Dec 18. Epub 2018 Dec 18.

National Centre for Biological Sciences, TIFR, GKVK Campus, Bellary Road, Bengaluru, India; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA. Electronic address:

Clozapine is an antipsychotic known for its superior efficacy in treating drug-resistant Schizophrenia. However, Clozapine induces various side effects such as hyperglycemia, agranulocytosis, weight gain etc. The mechanisms of these Clozapine-induced side effects have remained largely elusive though an important role is ascribed to 5-HT (Serotonin receptor subtype-2A). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jphs.2018.11.015DOI Listing
December 2018

A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries.

Asian J Psychiatr 2018 Dec 21;39:93-97. Epub 2018 Dec 21.

Hamad Medical Corporation, Mental Health Hospital, Doha, Qatar.

Clozapine is considered as the first line antipsychotic for treatment resistant schizophrenia (TRS). Worldwide reports indicate an overall underutilization of clozapine in patients experiencing TRS. This study aims to understand the prescribing practices, monitoring strategies and barriers to the use of clozapine in the Arabian Gulf (AG) region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajp.2018.12.011DOI Listing
December 2018

Severe acute pancreatitis with blood infection by Candida glabrata complicated severe agranulocytosis: a case report.

BMC Infect Dis 2018 Dec 29;18(1):706. Epub 2018 Dec 29.

Department of Emergency Internal Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New Area, Shanghai, 201203, People's Republic of China.

Background: Blood infection with Candida glabrata often occurs in during severe acute pancreatitis (SAP). It complicate severe agranulocytosis has not been reported.

Case Presentation: We present a case where a SAP patient presenting with a sudden hyperpyrexia was treated for 19 days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-018-3623-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310945PMC
December 2018
1 Read
2.613 Impact Factor

Intravenously administered cloxacillin-induced neutropenia with eosinophilia in a patient with infective endocarditis: a case report.

J Med Case Rep 2018 Dec 29;12(1):384. Epub 2018 Dec 29.

Teaching Hospital Kurunegala, Kurunegala, Sri Lanka.

Background: Bacteremia following Staphylococcus aureus is a serious clinical condition which is often associated with distant metastatic infections. One of the most dreaded complications of Staphylococcus aureus bacteremia is infective endocarditis. Cloxacillin is a common antibiotic prescribed for suspected staphylococcal infections and confirmed methicillin-sensitive Staphylococcus aureus infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-018-1933-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310943PMC
December 2018
1 Read

Levamisole-induced vasculitis.

JAAPA 2019 Jan;32(1):23-27

At the John S. Dunn Burn Center at Memorial Hermann Hospital, part of the University of Texas Health Science Center at Houston, Tex., Tonya C. George is an assistant professor of surgery, Daniel J. Freet is an assistant professor, James M. Cross is a professor of surgery, and Todd F. Huzar is an associate professor of surgery. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Levamisole is a veterinary antihelminthic, chemotherapeutic agent, and immunomodulator that also is used as an adulterant and cutting agent in cocaine distribution. This drug may potentiate the sympathomimetic actions of cocaine and can cause neutropenia, agranulocytosis, purpuric retiform lesions, and skin necrosis. This article describes two cases of suspected levamisole-induced vasculitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JAA.0000547746.08181.f7DOI Listing
January 2019
1 Read

Azathioprine-induced Agranulocytosis and Severe Alopecia After Kidney Transplantation Associated With a NUDT15 Polymorphism: A Case Report.

Transplant Proc 2018 Dec 18;50(10):3925-3927. Epub 2018 Apr 18.

Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. Electronic address:

Background: Azathioprine (AZA) is the drug recommended for the continuation of immunosuppressive treatment after renal transplant in women during pregnancy.

Case Report: A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy. Within 4 days of the initiation of AZA therapy, the patient developed a high fever, leucopenia, and cranial alopecia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.04.039DOI Listing
December 2018
1 Read

Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky.

Prim Care Companion CNS Disord 2018 Nov 29;20(6). Epub 2018 Nov 29.

PSTAR Clinic, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.18l02282DOI Listing
November 2018

Diagnostic workup in front of an adult neutropenia.

Ann Biol Clin (Paris) 2018 Dec;76(6):651-658

Service de médecine interne, Centre hospitalier de Royan, Vaux-sur-mer, France, Groupement de coopération sanitaire de Saintonge, Laboratoire inter-hospitalier de biologie médicale, Centres hospitaliers de Saint-Jean-d'Angély, Saintes, Royan et Jonzac, Saint-Jean-d'Angély.

Adult neutropenia, defined as a blood neutrophil count below 1.5 G/L, is a common condition. The most common cause of acute neutropenia is a drug-related reaction or an acute infectious disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2018.1393DOI Listing
December 2018

Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration.

Int J Hematol 2018 Dec 9. Epub 2018 Dec 9.

Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.

We present the case of a 63-year-old male with pure white cell aplasia (PWCA), a rare complication of thymoma, who was successfully treated with cyclosporine A (CyA) and thymectomy. The patient presented with high fever and agranulocytosis. Complete blood count revealed a white blood cell count of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-02573-yDOI Listing
December 2018
1 Read

[Agranulocytosis during therapy of chronic myeloid leukemia lymphoid blast crisis with dasatinib].

Rinsho Ketsueki 2018 ;59(11):2438-2440

Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.

A 61-year-old female was diagnosed with a lymphoid crisis of chronic myeloid leukemia (CML) in February 201X and started chemotherapy combined with dasatinib (DAS). After 1 month of initiating second consolidation therapy, the neutrophils decreased to 1%, bone marrow examination revealed large granular lymphocytes (LGL) at 13%, and complete cytogenetic remission was attained (CCyR). Suspecting DAS-induced agranulocytosis, DAS was discontinued. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/rinketsu/59/11/59_2438/
Publisher Site
http://dx.doi.org/10.11406/rinketsu.59.2438DOI Listing
January 2018
6 Reads

Quetiapine Induced Autoimmune Hemolytic Anemia in a Child Patient: A Case Report.

Clin Psychopharmacol Neurosci 2018 Nov;16(4):501-504

Departments of Child Hematology and Oncology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.

Autoimmune hemolytic anemia is a disease characterized with destruction of erythrocytes as a result of antibody produce against patient's own erythrocytes and anemia. Autoimmune hemolytic anemia can be roughly stratified into two groups according to serological features and secondary causes including drugs induced hemolytic anemia. Drugs induced autoimmune hemolytic anemia is very rare in pediatric patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.9758/cpn.2018.16.4.501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245293PMC
November 2018
1 Read

Effects of Clozapine on the Gut: Cross-Sectional Study of Delayed Gastric Emptying and Small and Large Intestinal Dysmotility.

CNS Drugs 2019 Jan;33(1):81-91

Department of Psychological Medicine, University of Otago, PO Box 7343, Wellington, 6242, New Zealand.

Background: Gastrointestinal hypomotility in people taking clozapine is common, poorly understood and potentially dangerous. It causes distress and sometimes sudden death, with greater associated morbidity than the better known adverse effect of clozapine, agranulocytosis. Neither the mechanism nor prevalence of clozapine-induced gastrointestinal hypomotility is well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-018-0587-4DOI Listing
January 2019
11 Reads

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

Background: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.

Methods: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). Read More

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805762
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805762DOI Listing
November 2018
9 Reads

Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency.

Allergy Asthma Clin Immunol 2018 22;14:65. Epub 2018 Oct 22.

1Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC Australia.

Background: Daclizumab is a humanized monoclonal antibody that blocks CD25, the high affinity alpha subunit of the interleukin-2 receptor. Daclizumab therapy targets T regulatory cell and activated effector T cell proliferation to suppress autoimmune disease activity, in inflammatory conditions like relapsing and remitting multiple sclerosis. Here, we present the first report of agranulocytosis with daclizumab therapy in a patient with relapsing and remitting multiple sclerosis. Read More

View Article

Download full-text PDF

Source
https://aacijournal.biomedcentral.com/articles/10.1186/s1322
Publisher Site
http://dx.doi.org/10.1186/s13223-018-0272-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196561PMC
October 2018
13 Reads

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.

BMC Neurol 2018 Oct 29;18(1):178. Epub 2018 Oct 29.

1st Department of Neurology, Medical School of Athens, National & Kapodistrian University, Aeginition Hospital, Athens, Greece.

Background: Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16% of treated MS-patients whereas severe neutropenia occurred in 0. Read More

View Article

Download full-text PDF

Source
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-
Publisher Site
http://dx.doi.org/10.1186/s12883-018-1183-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206708PMC
October 2018
8 Reads

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis.

Oxf Med Case Reports 2018 Nov 22;2018(11):omy094. Epub 2018 Oct 22.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan.

An 82-year-old man with a recurrence of pulmonary pleomorphic carcinoma was treated with pembrolizumab. He achieved partial response after three cycles of pembrolizumab. However, he developed febrile neutropenia. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/omcr/article/doi/10.1093/omcr/omy09
Publisher Site
http://dx.doi.org/10.1093/omcr/omy094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196766PMC
November 2018
7 Reads

Invasive Fungal Disease in Children with Acute Leukemia: The Elusive Culprit.

Indian J Pediatr 2018 12 16;85(12):1059-1060. Epub 2018 Oct 16.

Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12098-018-2802-1
Publisher Site
http://dx.doi.org/10.1007/s12098-018-2802-1DOI Listing
December 2018
5 Reads
0.920 Impact Factor

Fatal Agranulocytosis and Fournier's Gangrene due to the Use of Metamizole.

Indian J Pediatr 2018 Oct 16. Epub 2018 Oct 16.

Department of Pediatric Surgery, Cukurova University Faculty of Medicine, Adana, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12098-018-2799-5DOI Listing
October 2018
19 Reads

Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.

Front Pharmacol 2018 26;9:1049. Epub 2018 Sep 26.

Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical response and appearance of adverse events vary among individual patients receiving clozapine, with genetic and non-genetic factors potentially contributing to individual variabilities. Pharmacogenetic studies investigate associations between genetic variants and drug efficacy and toxicity. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fphar.2018.01049
Publisher Site
http://dx.doi.org/10.3389/fphar.2018.01049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169204PMC
September 2018
10 Reads

Implication of antibodies against human leukocyte antigen in simultaneous presentation of fetal and neonatal alloimmune thrombocytopenia and neutropenia.

Transfus Apher Sci 2018 Dec 29;57(6):773-776. Epub 2018 Sep 29.

Division of Neonatology, Department of Pediatrics, University of Washington, Seattle, WA, United States.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) and neonatal alloimmune neutropenia (NAN) are two rare complications of newborns caused by antibodies against paternal inherited antigens. Human platelet (HPA) and neutrophil antigens (HNA) are the common targets. Human leukocyte antigen (HLA) class I proteins are also expressed on platelets and neutrophils and anti-HLA antibodies have occasionally been implicated in these complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2018.09.018DOI Listing
December 2018
3 Reads

Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity?

Authors:
Rashmi R Shah

J Clin Pharm Ther 2019 Feb 11;44(1):129-133. Epub 2018 Oct 11.

Pharmaceutical Consultant, Buckinghamshire, UK.

What Is Known And Objective: Based on spontaneous reports from Spain, it is claimed that the British, Irish and Scandinavians are at a greater risk of dipyrone-induced agranulocytosis. This report examines the evidence.

Comment: Although interethnic differences in drug response are well known, there are no reliable epidemiologic data to support the above claim. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.12768DOI Listing
February 2019
12 Reads

Beta-lactam-induced severe neutropaenia: a descriptive study.

Fundam Clin Pharmacol 2018 Oct 5. Epub 2018 Oct 5.

Centre Régional de Pharmacovigilance, Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, 162 avenue Lacassagne, Lyon, 69424, France.

The objectives of this study were to describe the characteristics and natural history of beta-lactam-induced severe neutropaenia and to evaluate the risk of recurrences after another beta-lactam readministration. Reports of pure agranulocytosis associated with a beta-lactam exposure within the 10 days preceding the neutropaenia were extracted from the French Pharmacovigilance Database over the year 2010. Cases with another evident cause or more likely attributable to another drug were excluded. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/fcp.12419
Publisher Site
http://dx.doi.org/10.1111/fcp.12419DOI Listing
October 2018
4 Reads

Continuing Clozapine Treatment in Acute Psychosis With Neutropenia.

J Neuropsychiatry Clin Neurosci 2018 Oct 4:appineuropsych18060139. Epub 2018 Oct 4.

From the Department of Psychiatry, Taipei Medical University Hospital, Taipei, Taiwan (P-C L, K-H C); Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan (K-H C); and the Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (K-H C).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.neuropsych.18060139DOI Listing
October 2018
3 Reads

Trends in adverse drug reactions related hospitalisations over 13 years in New South Wales, Australia.

Intern Med J 2018 Oct 3. Epub 2018 Oct 3.

Research School of Population Health, Australian National University, Australia.

Aims: To examine trends in adverse drug reactions (ADR)-related hospitalisations in New South Wales (NSW).

Methods: Data were extracted from the Admitted Patient Data Collection (APDC), a census of hospital separations in NSW. We estimated age-adjusted rates of ADE-related hospitalisation between 1 July 2001 and 30 June 2014, and rates by patient characteristics, main therapeutic medication groups, and clinical condition groups that warranted the hospitalisation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/imj.14134
Publisher Site
http://dx.doi.org/10.1111/imj.14134DOI Listing
October 2018
2 Reads

Clozapine-Associated Cytomegalovirus Colitis and Related Critical Illness in a Patient With Neither Neutropenia Nor Agranulocytosis.

Ann Pharmacother 2018 Oct 3:1060028018805866. Epub 2018 Oct 3.

National Defense Medical Center, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018805866DOI Listing
October 2018
2 Reads

[Host Defense against Bacterial Infection and Bacterial Toxin-induced Impairment of Innate Immunity].

Authors:
Masaya Takehara

Yakugaku Zasshi 2018 ;138(10):1249-1253

Department of Microbiology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University.

 Whereas granulopoiesis during Gram-negative bacterial infection is accelerated through activation of toll-like receptor 4 (TLR4), it has not been elucidated whether Gram-positive bacterial infection can stimulate granulopoiesis. Using the well-known TLR2 agonist peptidoglycan (PGN), it was shown that neutrophils in bone marrow and spleen and plasma granulocyte colony-stimulating factor were increased in mice that had received intraperitoneal administration of PGN. Incorporation of bromodeoxyuridine into bone marrow neutrophils increased in mice administered PGN, demonstrating that PGN promotes granulopoiesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/yakushi.18-00102DOI Listing
October 2018
4 Reads

The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies.

Saudi Med J 2018 Sep;39(9):878-885

Department of Infectious Diseases & Clinical Microbiology, Izmir Bozyaka Training and Research hospital, University of Health Science, Izmir, Turkey. E-mail.

Objectives: To determine effective risk factors on mortality in febrile neutropenic cases with hematologic malignancy. Patients with hematologic diseases are more prone to infections and those are frequent causes of mortality.

Methods: This retrospective study was performed using data of 164 febrile neutropenic cases with hematologic malignancies who were followed up in a hematology clinic of a tertiary health care center between 2011-2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15537/smj.2018.9.22824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201010PMC
September 2018
2 Reads

The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia.

J Cancer Res Ther 2018 Sep;14(Supplement):S565-S570

Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuchang District, Wuhan, China.

Purpose: The occurrence of neutropenia following chemotherapy makes the management of myelosuppression important. The main objective of this study was to evaluate whether the decrease of peripheral blood monocytes was a potential indicator to predict the occurrence of neutropenia.

Patients And Methods: We retrospectively reviewed the medical records of 103 chemotherapy patients who underwent neutropenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0973-1482.177502DOI Listing
September 2018
1 Read

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.

BMC Cancer 2018 Sep 24;18(1):917. Epub 2018 Sep 24.

Medical Oncology, Institut Jules Bordet, Brussels, Belgium.

Background: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for patients receiving chemotherapy with FN risk of ≥20% or 10% to 20% with defined risk factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4838-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154917PMC
September 2018
1 Read

Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.

J Altern Complement Med 2018 Sep/Oct;24(9-10):954-961

2 Clinical Research Dr. Tröger (CRDT) , Freiburg, Germany .

Objectives: Evaluate the safety and clinical response of complementary treatment with European mistletoe extracts during chemotherapy.

Design: Monocentric controlled trial with 95 patients randomized into three groups.

Settings/location: National Cancer Research Center of Serbia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/acm.2018.0159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157372PMC
October 2018
2 Reads

Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.

Cancer Invest 2018 20;36(8):424-430. Epub 2018 Sep 20.

a Division of Respiratory Disease , Kumamoto Regional Medical Center , Kumamoto , Japan.

It is not clear whether sequential chemotherapy can be performed immediately in patients with p-stage I non-small cell lung cancer recurring during a 2-year period of daily oral administration with tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. Patients receiving chemotherapy within 1 month after the discontinuation of UFT (n = 10) (five cases with aggressive recurrent tumors) had the increased risk of grade 4 neutropenia, but the overall survival was not inferior to that in patients who received chemotherapy beginning more than 1 month (n = 11). We could perform sequential chemotherapy immediately while paying attention to grade 4 neutropenia. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/07357907.2018.1
Publisher Site
http://dx.doi.org/10.1080/07357907.2018.1515954DOI Listing
November 2018
8 Reads

Cytomegalovirus-associated haemophagocytic lymphohistiocytosis: a rare cause of febrile neutropenia during cancer chemotherapy.

BMJ Case Rep 2018 Sep 14;2018. Epub 2018 Sep 14.

Department of Haematology, Vejle Hospital, Vejle, Denmark.

Febrile neutropenia (FN) is a common complication in patients with cancer during treatment with antineoplastic drugs. The initial cause is usually bacterial, and treatment of FN follows well-defined algorithms. We report a case of a 62-year-old patient with chronic lymphocytic leukaemia (CLL), who developed FN, which was unresponsive to both empirical antibacterial and empirical antifungal therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-225592DOI Listing
September 2018
2 Reads

Influence of Modified Fucoidan and Related Sulfated Oligosaccharides on Hematopoiesis in Cyclophosphamide-Induced Mice.

Mar Drugs 2018 Sep 13;16(9). Epub 2018 Sep 13.

N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, 119991 Moscow, Russia.

Immunosuppression derived after cytostatics application in cancer chemotherapy is considered as an adverse side effect that leads to deterioration of quality of life and risk of infectious diseases. A linear sulfated (1→3)-α-l-fucan prepared by chemical modification of a fucoidan isolated from the brown seaweed , along with two structurally related synthetic sulfated oligosaccharides, were studied as stimulators of hematopoiesis on a model of cyclophosphamide immunosuppression in mice. Recombinant granulocyte colony-stimulating factor (), which is currently applied in medicine to treat low blood neutrophils, was used as a reference. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1660-3397/16/9/333
Publisher Site
http://dx.doi.org/10.3390/md16090333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164909PMC
September 2018
7 Reads
2.853 Impact Factor

A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment.

Clin Case Rep 2018 Sep 10;6(9):1701-1703. Epub 2018 Jul 10.

Division of Endocrinology and Metabolism Department of Internal Medicine College of Medicine Seoul St. Mary's Hospital The Catholic University of Korea Seoul Korea.

Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132132PMC
September 2018
5 Reads

Pain-prescription differences - an analysis of 500,000 discharge summaries.

Curr Drug Abuse Rev 2018 Sep 10. Epub 2018 Sep 10.

Structural Bioinformatics Group, Experimental and Clinical Research Centre, Charite - University Medicine Berlin, Berlin. Germany.

Background: Pain-relief prescriptions have led to an alarming increase in drug-related abuse. In this study we estimate the pain reliever prescription rates at a major German academic hospital center and compare with the nationwide trends from Germany and prescription reports from the USA.

Methods: We analysed >500,000 discharge summaries from Charite, encompassing the years 2006 to 2015, and extracted the medications and diagnoses from each discharge summary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874473711666180911091846DOI Listing
September 2018
2 Reads

Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies.

Transpl Infect Dis 2018 Dec 21;20(6):e12994. Epub 2018 Sep 21.

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) is associated with high mortality in patients with hematologic malignancies (HM). We sought to determine whether allogeneic hematopoietic cell transplant (allo-HCT) recipients would be at higher risk for 60-day mortality.

Methods: We examined a retrospective cohort of adults with HM with or without HCT treated for RSV LRTI (n = 154) at our institution from 1996-2013. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/tid.12994
Publisher Site
http://dx.doi.org/10.1111/tid.12994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329612PMC
December 2018
7 Reads

Granulocytopenia.

Vnitr Lek 2018 ;64(5):520-525

Granulocytopenia is defined as a decrease of peripheral blood granulocytes below lower limit of normal range. Patients with severe granulocytopenia - agranulocytosis exhibit < 0.5 × 109/l granulocytes in peipheral blood. Read More

View Article

Download full-text PDF

Source
January 2018
4 Reads

Management of common adverse effects of antipsychotic medications.

World Psychiatry 2018 Oct;17(3):341-356

Department of Psychiatry, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.

The benefits of antipsychotic medications are sometimes obscured by their adverse effects. These effects range from relatively minor tolerability issues (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wps.20567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127750PMC
October 2018
2 Reads

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

Background: Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.

Methods: We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Read More

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018
20 Reads
55.873 Impact Factor

Agranulocytosis Induced by Vancomycin. Case Report and Literature Review.

Am J Case Rep 2018 Sep 3;19:1053-1056. Epub 2018 Sep 3.

Department of Internal Medicine, Hospital de Clínicas "José de San Martin", University of Buenos Aires, Buenos Aires, Argentina.

BACKGROUND Vancomycin has been used for decades to treat infections by Gram-positive bacteria, particularly those caused by methicillin-resistant staphylococci. Agranulocytosis is an infrequent complication of this antibiotic, postulated in its genesis a mechanism immune-mediated by antineutrophil antibodies and antineutrophil cytoplasm antibodies (ANCA). Treatment includes discontinuing vancomycin, and granulocyte colony-stimulating factor administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.909956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135043PMC
September 2018
10 Reads

Spectrum of mutations in congenital neutropenia: a single-centre study in patients of Indian origin.

J Clin Pathol 2018 Dec 31;71(12):1046-1050. Epub 2018 Aug 31.

Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India

Aims: Congenital and cyclical neutropenia are rare inherited diseases that result in recurrent life-threatening bacterial infections due to a deficiency of mature neutrophils. Cyclical neutropenia is usually caused by heterozygous mutations while congenital neutropenia is genetically heterogeneous with mutations in genes like and The presence of mutation aids in the establishment of diagnosis and rules out other secondary causes of neutropenia such as autoimmune cytopenia and evolving aplasia. Further, patients with mutations are also at a high risk of developing myelodysplasia or acute myeloid leukaemia. Read More

View Article

Download full-text PDF

Source
http://jcp.bmj.com/lookup/doi/10.1136/jclinpath-2018-205235
Publisher Site
http://dx.doi.org/10.1136/jclinpath-2018-205235DOI Listing
December 2018
15 Reads
2.920 Impact Factor

Agranulocytosis and Good Syndrome in Patient with Thymoma-The Role of Immunosuppressive Treatment after Thymectomy.

J Thorac Oncol 2018 Sep;13(9):e177-e178

Department of Hematology, Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183059
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.04.037DOI Listing
September 2018
19 Reads

Disseminated fusariosis with cutaneous involvement in hematologic malignancies: report of six cases with high mortality rate.

An Bras Dermatol 2018 Sep-Oct;93(5):726-729

Department of Dermatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo (SP), Brazil.

Fusariosis is due to inhalation or direct contact with conidia. Clinical presentation depends on host's immunity and can be localized, focally invasive or disseminated. Given the severity of this infection and the possibility for the dermatologist to make an early diagnosis, we report six cases of patients with hematologic malignancies, who developed febrile neutropenia an skin lesions suggestive of cutaneous fusariosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20187476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106674PMC
October 2018
5 Reads

Poikiloderma with neutropenia and associated squamous cell carcinoma: A case report.

Pediatr Dermatol 2018 Nov 28;35(6):e366-e367. Epub 2018 Aug 28.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Here, we describe a case of a patient with known poikiloderma with neutropenia who developed cutaneous squamous cell carcinoma in a chronically sun-exposed area at the age of 14. To date, there is only one other report of this association. This report highlights the need for routine skin cancer screening in patients with this diagnosis as well as the importance of a correct initial diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13645DOI Listing
November 2018
4 Reads

Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.

Oncology 2018 27;95(5):281-287. Epub 2018 Aug 27.

Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.

Objective: Neoadjuvant therapy followed by surgery has been the standard treatment for advanced esophageal cancer. Severe toxicities may influence body composition, including skeletal muscle mass, and increase postoperative complications. The purpose of this study was to evaluate the influence of sarcopenia, changes in body composition, and adverse events during neoadjuvant chemotherapy (NACT) on postoperative complications in esophageal cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490616DOI Listing
November 2018
2 Reads

Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.

Pediatr Nephrol 2019 Jan 23;34(1):87-96. Epub 2018 Aug 23.

Department of Pediatrics, Hokkaido University Graduate School of Medicine, North 15, West 7, Sapporo, Hokkaido, 060-8638, Japan.

Background: Rituximab (RTX) is effective in maintaining remission in patients with nephrotic syndrome (NS), but a standard protocol of RTX administration has not been established.

Methods: This study was a 2-year multicenter observational study, in which consistent treatments and evaluations were performed. We enrolled pediatric patients with refractory NS between January 2015 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00467-018-4063-7DOI Listing
January 2019
14 Reads